Nut midline carcinoma
MONDO:0005563A rare, highly aggressive and lethal carcinoma that affects children and young adults. It arises from midline epithelial structures, most commonly the head, neck, and mediastinum. It is a poorly differentiated carcinoma and is characterized by mutations and rearrangement of the NUT gene. A balanced translocation t(15;19) is present that results in the creation of a fusion gene involving the NUT gene, most commonly BRD4-NUT fusion gene.
Also known as: Midline carcinoma of children and Young adults with NUT rearrangement, NMC, NUT Midline carcinoma, NUT carcinoma, carcinoma with t(15;19)(q13;p13.1) translocation, nuclear protein in testis midline carcinoma, NUT midline carcinoma of the head and neck
2751 clinical trials for this condition and its sub-types, 6 tagged with Nut midline carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Immunotherapy drug cemiplimab takes on rare, incurable cancer
Disease control Recruiting nowThis phase 2 trial is testing whether the immunotherapy drug cemiplimab can help people with NUT carcinoma, a rare and aggressive cancer that has spread or cannot be removed by surgery. The study will enroll 15 participants and measure how long they live and whether their tumors …
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests the safety and best dose of two drugs, ZEN003694 and abemaciclib, given together. It is for people with advanced breast cancer, NUT carcinoma, or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the combinatio…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Promising new combo tackles rare, aggressive cancer
Disease control Recruiting nowThis study tests a new drug, ZEN003694, combined with standard chemotherapy for people with a rare and aggressive cancer called NUT carcinoma. The goal is to find the safest dose and see if the combination shrinks tumors. About 36 adults with advanced or spreading NUT carcinoma w…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New study targets lung cancer in the young: what makes it different?
Knowledge-focused Recruiting nowThis study aims to learn more about lung cancer in adults diagnosed at age 45 or younger. Researchers will collect blood samples and medical information from 500 participants to study the biology of these cancers and look for genetic changes that could lead to better treatments. …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC